Coya Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Coya Therapeutics şirketinin toplam hissedar öz sermayesi $32.0M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $35.6M ve $3.5M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$31.06m
Eşitlik	US$32.01m
Toplam yükümlülükler	US$3.54m
Toplam varlıklar	US$35.55m

Son finansal sağlık güncellemeleri

Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth

Oct 29

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Mar 26

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Sep 06

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

May 17

Recent updates

Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth

Oct 29

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Oct 13

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Mar 26

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Feb 13

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Jan 13

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Sep 06

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

May 17

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: COYA 'nin kısa vadeli varlıkları ( $35.5M ) kısa vadeli yükümlülüklerini ( $2.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: COYA şirketinin kısa vadeli varlıkları ( $35.5M ) uzun vadeli yükümlülüklerini ( $1.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: COYA borçsuzdur.

Borcun Azaltılması: COYA un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: COYA şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: COYA serbest nakit akışı her yıl % 30.5 1.1 yıl yetecek nakit akışına sahip olacaktır.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/24 23:39
Gün Sonu Hisse Fiyatı	2025/01/24 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Coya Therapeutics, Inc. 6 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Thomas Shrader	BTIG
Keay Nakae	Chardan Capital Markets, LLC
Jason Kolbert	D. Boral Capital LLC.

Coya Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

Recent updates

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

Coya Therapeutics, Inc. Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (Ld Il-2) + Ctla4-Ig Fusion Protein in Patients with Frontotemporal Dementia (Ftd)

New minor risk - Market cap size

Consensus revenue estimates decrease by 27%, EPS upgraded

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)

Companies Like Coya Therapeutics (NASDAQ:COYA) Can Afford To Invest In Growth

Coya Therapeutics, Inc. announced that it expects to receive $10.000027 million in funding

Coya Therapeutics Has Several Near-Term Share Price Appreciation Catalysts

Consensus EPS estimates fall by 10%

New minor risk - Share price stability

Coya Therapeutics, Inc. Announces CEO Changes, Effective November 1, 2024

Consensus revenue estimates fall by 24%

Coya Therapeutics, Inc. Submits an Investigational New Drug Application

Consensus revenue estimates fall by 44%

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

New major risk - Shareholder dilution

Coya Therapeutics, Inc. announced that it has received $4.999997 million in funding from Alzheimers Drug Discovery Foundation

Consensus revenue estimates increase by 64%, EPS downgraded

Coya Therapeutics, Inc., Annual General Meeting, May 08, 2024

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Coya Therapeutics, Inc. Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Coya Therapeutics In Catbird Seat Following Dr. Reddy's Licensing Deal

Consensus revenue estimates increase by 100%

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

Coya Therapeutics: Interesting Early Data In CNS Diseases, Very Low Cash Position

Coya Therapeutics, Inc. Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of Coya 302 for Treatment of Amyotrophic Lateral Sclerosis

Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding

Coya Therapeutics, Inc. announced that it has received $26.484515 million in funding

Wilbur Ross Joins Coya Therapeutics' Board

Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding

Coya Therapeutics, Inc. announced that it expects to receive $26.484515 million in funding

Coya Therapeutics, Inc. Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis

New minor risk - Share price stability

Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting

Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple Diseases

We Think Coya Therapeutics (NASDAQ:COYA) Needs To Drive Business Growth Carefully

Coya Therapeutics, Inc. Reports the Publication of a Research Article Entitled “Immunological, Oxidative, and Structural Factors and Their Responses T Lymphocyte Therapy in Amyotrophic Lateral Sclerosis”

Coya Therapeutics, Inc. Appoints Dieter Weinand to Its Board of Directors

New major risk - Financial position

Coya Therapeutics, Inc. Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor

Coya Therapeutics Reports Additional Proof-Of-Concept Clinical Biomarker Data in Patients with Alzheimer's Disease

Coya Therapeutics, Inc. Announces Management Changes, Effective July 17, 2023

Coya Therapeutics, Inc. to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. Appoints Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs

Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer's Disease (AD)

Coya Therapeutics, Inc. Announces Appointment of Dr. Guillaume Dorothée to Scientific Advisory Board

Coya Therapeutics, Inc., Annual General Meeting, Jun 28, 2023

Coya Therapeutics, Inc. Reports Results from an Open-Label Proof-Of-Concept Clinical Study for COYA 301 in patients with AD. Results of the study

Here's Why We're Watching Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

Coya Therapeutics, Inc. Announces Preclinical Data Supporting the Role of Expanded Regulatory T Cells (Tregs) as Potential Disease-Modifying Treatment in an Animal Model of Alzheimer’s Disease (AD)

Coya Therapeutics, Inc. has completed an IPO.

High number of new and inexperienced directors

Coya Therapeutics, Inc. has completed an IPO.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları